Credit Agricole S A Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Credit Agricole S A reduced its stake in Regeneron Pharmaceuticals by 47% in Q1, ending up with 5,898 shares worth approximately $3.74 million.
• The average rating for Regeneron Pharmaceuticals stocks is currently a "Moderate Buy" with an average price target of $829.65 as several analysts updated their ratings and price objectives recently.
• Regeneron reported a strong quarterly earnings result, with earnings per share of $12.89, significantly exceeding analyst expectations of $8.43.

Credit Agricole S A reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 47.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,898 shares of the biopharmaceutical company's stock after selling 5,224 shares during the quarter. Credit Agricole S A's holdings in Regeneron Pharmaceuticals were worth $3,741,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Pinney & Scofield Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its position in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 31 shares in the last quarter. Costello Asset Management INC acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. Tompkins Financial Corp acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $32,000. Finally, Curat Global LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $32,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on REGN shares. Argus lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Morgan Stanley reissued an "overweight" rating and issued a $761.00 price objective (up from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Guggenheim raised their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a report on Friday, August 1st. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $829.65.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $589.48 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The business's 50 day moving average price is $550.48 and its 200-day moving average price is $592.20. The firm has a market capitalization of $62.48 billion, a PE ratio of 14.86, a P/E/G ratio of 1.99 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The firm had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business's revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the company posted $11.56 earnings per share. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.